Analysts’ Recent Ratings Updates for Infinity Pharmaceuticals (INFI)
Infinity Pharmaceuticals (NASDAQ: INFI) was the recipient of a ratings changes during the seven days:
- Infinity Pharmaceuticals was upgraded by analysts at Wedbush from an “underperform” rating to a “neutral” rating. They now have a $15.00 price target on the stock, up previously from $9.00.
- Infinity Pharmaceuticals had its “positive” rating reaffirmed by analysts at Roth Capital.
- Infinity Pharmaceuticals had its price target raised by analysts at Jefferies Group from $13.00 to $18.00. They now have a “buy” rating on the stock.
- Infinity Pharmaceuticals was upgraded by analysts at JMP Securities from a “market perform” rating to an “outperform” rating. They now have a $24.00 price target on the stock.
Infinity Pharmaceuticals Inc. (NASDAQ:INFI) traded down 6.87% during mid-day trading on Thursday, hitting $14.65. 4,995,380 shares of the company’s stock traded hands. Infinity Pharmaceuticals Inc. has a one year low of $8.40 and a one year high of $21.60. The stock’s 50-day moving average is $10.58 and its 200-day moving average is $11.34. The company’s market cap is $711.8 million. Infinity Pharmaceuticals also was the recipient of unusually large options trading on Wednesday. Stock investors purchased 10,671 put options on the stock. This represents an increase of 1,206% compared to the typical volume of 817 put options.
Infinity Pharmaceuticals (NASDAQ:INFI) last announced its earnings results on Tuesday, August 5th. The company reported ($0.78) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.84) by $0.06. During the same quarter last year, the company posted ($0.68) earnings per share. Infinity Pharmaceuticals’s revenue was up NaN% compared to the same quarter last year. On average, analysts predict that Infinity Pharmaceuticals Inc. will post $-3.48 earnings per share for the current fiscal year.
Infinity Pharmaceuticals, Inc (NASDAQ:INFI) is a drug discovery and development company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.